Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).

Yun Zhang,Jianming Xu,Jie Shen,Shanzhi Gu,Lihua Wu,Jian Wu,Guoliang Shao,Yanqiao Zhang,Li Xu,Tao Yin,Jingfeng Liu,Zhenggang Ren,Jianping Xiong,Xianhai Mao,Ling Zhang,Jiayin Yang,Le-Qun Li,Xiaoming Chen,Zhiming Wang,Quanren Wang

Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).

2021

4076Background: C+A combination therapy displayed high objective response rate, disease control rate, and durable response with a manageable safety profile in patients (pts) with advanced HCC. Here...

Keywords:

safety profile
Medicine
Combination therapy
Internal medicine
Hepatocellular carcinoma
objective response
Oncology
in patient
overall survival
open label
Apatinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations